Treatment failure in osteoporosis
- PMID: 22836278
- DOI: 10.1007/s00198-012-2093-8
Treatment failure in osteoporosis
Abstract
Guidelines concerning the definition of failure of therapies used to reduce the risk of fracture are provided.
Introduction: This study aims to provide guidelines concerning the definition of failure of therapies used to reduce the risk of fracture.
Methods: A working group of the Committee of Scientific Advisors of the International Osteoporosis Foundation was convened to define outcome variables that may assist clinicians in decision making.
Results: In the face of limited evidence, failure of treatment may be inferred when two or more incident fractures have occurred during treatment, when serial measurements of bone remodelling markers are not suppressed by anti-resorptive therapy and where bone mineral density continues to decrease.
Conclusion: The provision of pragmatic criteria to define failure to respond to treatment provides an unmet clinical need and may stimulate research into an important issue.
Comment in
-
Treatment failure in osteoporosis.Climacteric. 2012 Dec;15(6):632-3. doi: 10.3109/13697137.2012.733634. Climacteric. 2012. PMID: 23174020 No abstract available.
Similar articles
-
One year in review 2018: progress in osteoporosis treatment.Clin Exp Rheumatol. 2018 Nov-Dec;36(6):948-958. Epub 2018 Dec 6. Clin Exp Rheumatol. 2018. PMID: 30526765 Review.
-
Goal-directed treatment of osteoporosis in Europe.Osteoporos Int. 2014 Nov;25(11):2533-43. doi: 10.1007/s00198-014-2787-1. Epub 2014 Sep 9. Osteoporos Int. 2014. PMID: 25199574
-
Review of the guideline of the American College of Physicians on the treatment of osteoporosis.Osteoporos Int. 2018 Jul;29(7):1505-1510. doi: 10.1007/s00198-018-4504-y. Epub 2018 Jun 4. Osteoporos Int. 2018. PMID: 29869039 Free PMC article. Review.
-
Management of glucocorticoid-induced osteoporosis: What is new?Int J Rheum Dis. 2019 Sep;22(9):1595-1597. doi: 10.1111/1756-185X.13680. Int J Rheum Dis. 2019. PMID: 31478605 No abstract available.
-
Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).Osteoporos Int. 2015 Feb;26(2):765-74. doi: 10.1007/s00198-014-2964-2. Epub 2014 Nov 18. Osteoporos Int. 2015. PMID: 25403903 Clinical Trial.
Cited by
-
Molecular Signaling Pathways and MicroRNAs in Bone Remodeling: A Narrative Review.Diseases. 2024 Oct 12;12(10):252. doi: 10.3390/diseases12100252. Diseases. 2024. PMID: 39452495 Free PMC article. Review.
-
[Osteoporosis-Definition, risk assessment, diagnosis, prevention and treatment (update 2024) : Guidelines of the Austrian Society for Bone and Mineral Research].Wien Klin Wochenschr. 2024 Oct;136(Suppl 16):599-668. doi: 10.1007/s00508-024-02441-2. Epub 2024 Oct 2. Wien Klin Wochenschr. 2024. PMID: 39356323 Free PMC article. German.
-
Decisive gene strategy on osteoarthritis: a comprehensive whole-literature based approach for conclusive gene targets.Aging (Albany NY). 2024 Sep 6;16(17):12346-12378. doi: 10.18632/aging.206094. Epub 2024 Sep 6. Aging (Albany NY). 2024. PMID: 39248710 Free PMC article.
-
Change in body temperature, not acute-phase reaction, predict anti-Osteoporosis efficacy after the first administration of Zoledronic acid: a prospective observational cohort study.BMC Musculoskelet Disord. 2024 Sep 2;25(1):694. doi: 10.1186/s12891-024-07781-8. BMC Musculoskelet Disord. 2024. PMID: 39223504 Free PMC article.
-
Clinical effects of teriparatide, abaloparatide, and romosozumab in postmenopausal osteoporosis.J Bone Miner Metab. 2024 Jul 15. doi: 10.1007/s00774-024-01536-0. Online ahead of print. J Bone Miner Metab. 2024. PMID: 39009890 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
